Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Novocure Ltd NVCR

Healthcare Medical Devices
NovoCure Limited is a global oncology company. The Company is engaged in the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua for the treatment of solid tumor cancers. Its commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, malignant pleural mesothelioma and... see more

Recent & Breaking News (NDAQ:NVCR)

Novocure Announces Last Patient Enrolled in Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-small Cell Lung Cancer

Business Wire November 22, 2021

2-THE-TOP Phase 2 Trial Reports Positive Top-Line Results in Newly Diagnosed Glioblastoma

Business Wire November 15, 2021

Novocure Announces Last Patient Enrolled in Phase 3 Pivotal INNOVATE-3 Trial of Tumor Treating Fields in Ovarian Cancer

Business Wire October 28, 2021

Novocure Reports Third Quarter 2021 Financial Results and Provides Company Update

Business Wire October 28, 2021

Novocure Announces 15 Presentations at the American Society for Radiation Oncology 2021 Annual Meeting

Business Wire October 21, 2021

Zai Lab and Novocure Announce Last Patient Enrolled in Phase 2 Pilot Trial of Tumor Treating Fields Plus Chemotherapy as First-Line Treatment in Gastric Cancer in China

GlobeNewswire October 4, 2021

Novocure to Report Third Quarter 2021 Financial Results

Business Wire October 4, 2021

Novocure and Zai Lab Announce Last Patient Enrolled in Phase 2 Pilot Trial of Tumor Treating Fields Plus Chemotherapy as First-Line Treatment in Gastric Cancer in China

Business Wire October 4, 2021

Novocure Announces Clinical Trial Collaboration with Roche to Evaluate Tumor Treating Fields as Part of a Novel Combination for the First-line Treatment of Metastatic Pancreatic Cancer

Business Wire September 14, 2021

FDA Grants Breakthrough Device Designation to the NovoTTF-200T(TM) System for Advanced Liver Cancer

Business Wire September 9, 2021

Novocure to Participate in the 2021 Wells Fargo Virtual Healthcare Conference

Business Wire September 2, 2021

Novocure Appoints Bill Burke as Chief Human Resources Officer

Business Wire September 1, 2021

Novocure Reports Second Quarter 2021 Financial Results and Provides Company Update

Business Wire July 29, 2021

Novocure Announces Recipients of 3rd Annual AACR-Novocure Grants for Tumor Treating Fields Research Program

Business Wire July 15, 2021

Novocure to Report Second Quarter 2021 Financial Results

Business Wire July 8, 2021

Novocure Presents Final Safety and Efficacy Results from its Phase 2 Pilot HEPANOVA Trial in Liver Cancer

Business Wire July 1, 2021

Novocure Initiates Usability Study for Flexible Torso Array

Business Wire June 16, 2021

Novocure Announces Clinical Trial Collaboration with GT Medical Technologies to Evaluate Tumor Treating Fields Together with GammaTile® Therapy in Recurrent Glioblastoma

Business Wire May 25, 2021

Zai Lab Announces First Patient Treated in Greater China in METIS Phase 3 Pivotal Trial of Tumor Treating Fields in Brain Metastases from Non-Small Cell Lung Cancer

GlobeNewswire May 24, 2021

Novocure Announces FDA Approval of IDE Supplement for Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-Small Cell Lung Cancer

Business Wire May 18, 2021